QNCX, US22053A1079

IRulya schedules October 22 conference: ticker for Quince Therapeutics stock changes to IRLA

Published on 10/16/2026 at 00:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash stood at USD 116 million on June 30, 2026. Quince Therapeutics stock enters a new phase with LAM-001 studies.

Corporate transition and clinical timing

IRulya announced its October 22, 2026 conference appearance.
Cash stood at USD 116 million as of June 30, 2026.
QNCX stockholders approved the share issuance on October 6, 2026.

QNCX, US22053A1079, Illustration mit AI erstellt.

Quince Therapeutics stock is entering a new corporate phase after the company changed its name to IRulya Therapeutics and shifted its trading symbol to IRLA on October 12, 2026. The latest event is a planned October 22 conference appearance, while the company advances LAM-001 across three Phase 2 programs.

October 22 event adds a near-term date

IRulya will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026, according to BioSpace. The company said a replay will be posted in the investor events section after the presentation.

The clinical pipeline is the central valuation reference. The investor-relations page lists an ongoing Phase 2 study in bronchiolitis obliterans syndrome, an ongoing Phase 2b study in pulmonary hypertension associated with interstitial lung disease, and a planned Phase 2 study in sarcoidosis-associated pulmonary hypertension during the fourth quarter of 2026, according to IRulya Therapeutics.

What changed in the relaunch?

Chronology puts the transition in context. On October 6, 2026, stockholders approved an issuance tied to preferred-stock conversion, warrants and legacy options that would represent more than 20 percent of outstanding common shares, according to StockTitan. On October 9, 2026, the company relaunched as IRulya and disclosed cash of USD 116 million as of June 30, 2026. On October 12, 2026, the stock began trading under IRLA on the Nasdaq Capital Market, as reported by GlobeNewswire.

Which dates matter next?

The next scheduled corporate date is October 22, 2026, when senior management is due to present at the Craig-Hallum conference. The next clinical timing marker is the first quarter of 2027, when IRulya anticipates data from the BOS study, according to the company release linked by GlobeNewswire. That sequence leaves clinical readouts, rather than revenue, as the main near-term company-specific milestone.

Corporate identity now leads the stock story

IRulya is developing LAM-001, an inhaled rapamycin formulation, for three serious pulmonary diseases. The company also appointed Brigette Roberts as CEO, John Militello as CFO and Keith Fandrick as COO effective in October 2026, according to the October 9 company release.